Omalizumab in recurring larynx angioedema: a case report
10.5415/apallergy.2014.4.2.129
- Author:
Ayse Bilge OZTURK
1
;
Emek KOCATURK
Author Information
1. Adult Allergy Unit, Göztepe Tainning and Research Hospital, Istanbul Medeniyet University, Istanbul 34469, Turkey. aysebilgeozturk@yahoo.com
- Publication Type:Case Report
- Keywords:
Omalizumab;
Angioedema;
Larynx
- MeSH:
Angioedema;
Asthma;
Histamine Antagonists;
Humans;
Hypersensitivity;
Larynx;
Lip;
Male;
Middle Aged;
Omalizumab;
Urticaria
- From:
Asia Pacific Allergy
2014;4(2):129-130
- CountryRepublic of Korea
- Language:English
-
Abstract:
Angioedema with swelling of larynx is a serious allergic reaction and can be life-threatening. It can occur after exposure to various triggers and usually it is very difficult for the patient and the doctor to find the trigger and maintain complete remission. In idiopathic recurring angioedema presenting with frequent attacks, prophylaxis with H₁ antihistamines recommended. However, not all patients respond to antihistamines. Omalizumab is an anti-immunoglobulin (Ig)-E-Ig-G antibody approved for the treatment of asthma and also effective treatment in chronic spontaneous urticaria. We report a 47-year-old male patient with severe idiopathic angioedema controlled by corticosteroid and proggressed after discontining of corticosteroid because of its side effects. Omalizumab at a dose of 300 mg every 4 weeks was administrated and omalizumab provided a rapid clinical response after first injection. During the 4 months of omalizumab therapy, he had no further attacks and any other treatment needs. After 3 months of stopping omalizumab therapy, during the 4-week period he had two mild lip swelling in his lips that resolved with antihistamines.
